Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| argenx to Present at Upcoming Investor Conferences | ||
| By: GlobeNewswire - 26 Feb 2024 | Back to overview list |
|
February 26, 2024
Additional information regarding these events will be available on the Investors section of the argenx website at argenx.com/investors. About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, Israel, the EU, the UK, Canada and China. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram HYPERLINK "http://www.instagram.com/argenxglobal". For further information, please contact: Media: Ben Petok Investors: Alexandra Roy (US) Lynn Elton (EU) 
|
||
|
||
 | Back to overview list | |